Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGX-001 in p47-CGD
NCT07826767Phase 2Recruiting
- Sponsor
- Somagenetix
- Start
- Aug 2026
- Primary completion
- Jul 2028
- Countries
- 3
01
Overview
A Phase 2 trial of SGX-001 in chronic granulomatous disease (CGD), sponsored by Somagenetix. Started Aug 2026; status: recruiting.
02
Drugs
SGX-001
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT07826767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07826767.